BACKGROUND: Promoter hypermethylation and global hypomethylation in the human genome are hallmarks of most cancers. OBJECTIVE: The aim of this study is to assess the methylation profile patterns of TWIST gene and to investigate the relationship of methylation with pathological features. METHODS: Romoter CpGisland methylation of TWIST which can be related in breast cancer was performed by methylation-sensitive high resolution melting (MS-HRM) analysis. Formalin-fixed, paraffin-embedded (FFPE) tissue samples of 80 patients with a diagnosis of primary breast cancer from Eskisehir Osmangazi University medical faculty of Oncology Clinic were included. RESULTS: In our study, the promoter hypermethylation frequency of TWIST gene was 25.0%. With these results, when the prognostic factors of the patients were analyzed, tumor stage and age were found to be meaningless with the hypermethylation of TWIST gene, but found to be significant with lymph node positivity, ER positivity, PR negativity, and HER2/NEU negativity.
reported, and silencing of these genes plays important roles in carcinogenesis and tumor progression [2] [3] [4] [5] . Identification of epigenetic changes and their correlation with other clinical factors could lead to improvements in cancer diagnosis and treatment.
Human basic helix-loop-helix DNA binding protein (TWIST; location: 7p21.2; GenBank: U80998) induces E-cadherin mediated cell-cell adhesion and induction of cell motility. Increased expression of TWIST correlates with tumor invasion and metastasis [6] .
DNA methylation is the epigenetic change, which has been mostly reported to be associated with TWIST and interfere with Twist expression. Usually, hypermethylation of the promoter region of TWIST gene has been known in certain cancers of breast, uterine cervix, ovary, bladder, colorectal, gastric, lung, bone and brain [7] . For the detection of cancer cells and cancer typing in biological samples, the tumor specific promoter hypermethylation of TWIST is becoming a promising tool. However, it is not very clear how the TWIST promoter hypermethylation is responsible for carcinogenesis. Evidences showed that the increased frequency of hypermethylated genes in distant metastasis might be an important event in cancer progression. It has been reported that the hypermethylated TWIST gene is more frequently found in the local and distant metastasis than in primary breast carcinomas [8] . To clarify the epigenetic mechanism of Twist, Gort [9] proposed two possibilities: [10] the proximal part of the TWIST promoter is not related to TWIST expression, rather than interfering with other genes in genomic proximity like HDAC9 and FERD3L; [7] hypermethylation of TWIST promoter might be an early event that precedes compensatory TWIST over-expression [11] . Chromatin remodeling is another important epigenetic change of Twist responsible for cancer. Evidence showed that a protein complex formed by Twist with the Mi2/nucleosome remodeling and deacetylase, termed as Twist/Mi2/NuRD, plays an essential role in invasive and metastatic cancer cells [12] . miR-10b has also been reported to target Twist but change of miR-10b expression alone can't induce breast cancer cell into EMT [13] , and other factors might be associated. However, these mechanisms are not enough to understand the epigenetics of Twist in cancer clearly, and a vast things to know. In cancer therapeutics, controlling metastasis remains one of the mainstream focuses, and targeting Twist might be the new dimension in controlling metastatic cancers. Several attempts have been taken to manipulate Twist function in cancer cells, including epigenetic approaches. Particularly, in hormone resistant breast cancer, epigenetic modification of Twist is able to restore hormone sensitivity, as Twist can serve as a potential target for converting estrogen receptor (ER)-α-negative breast cancers to ER-α-positive breast cancers [14] [15] . Exploring Twist epigenetics might be a very interesting topic for the cancer researchers for the invention of new therapeutic approach for cancer treatment. 
Bisulphite Modification and Methylation Analysis
Approximately 250 -500 nanogram of genomic DNA was bisulphite modified Unmethylated DNA were used as the fully methylated and unmethylated controls, respectively. Methylation standards (25%, 50%, 75% and 100%) made by diluting the fully methylated control in the unmethylated DNA were used as controls. Whole-genome amplification (WGA) was also used to make a fully unmethylated control and performed as described previously [19] .
Statistical Analysis
The v2 test and binary logistic regression were used to analyse the relationship of methylation with the clinicopathological findings. The analyses were carried out with SPSS version 15.0 (SPSS Inc., Chicago, IL). A two tailed P-value of less than 0.05 was considered to be statistically significant for each comparison.
Results

Patient Characteristics
Patient characteristics included in this study are summarised in 
Methylation Status in Primary Breast Tumor Samples
A summary of the promoter methylation analysis of TWIST gene in 80 primary breast tumours are shown in Table 3 and Table 4 and examples of the MS-HRM results are shown in Figures 1-3 . Mentioned gene showed detectable promoter methylation in primary breast tumours. TWIST1, was methylated in 25% of primary breast tumors.
Correlation between DNA Methylation and Clinicopathological Parameters
When the only methylated groups were compared, there is no correlation between the TWIST gene hypermethylation and tumor stage (p > 0.05) and age O. Eroglu et al. 
Discussion
Aberrant promoter DNA methylation has been examined with various methodologies, including COBRA, SSCP, MSP and sequencing [20] . MSP is currently the most widely used method due to its claimed efficiency in heterogeneous cancer cell populations [21] . On the other hand it has limitations since it is time-consuming, more expensive and not quantitative in comparison with MS-HRM [20] . MS-HRM is a novel approach to identify aberrant methylation of gene promoter regions using sequence-dependent melting profiles of each amplicon [22] . It has been considered as the most rapid and Furthermore, MS-HRM is a semi-quantitative method that has been claimed to distinguish homogeneous from heterogeneous methylation [23] . TWIST belongs to the basic-helix-loop-helix family of transcription factors and is implicated in lineage-specific cellular differentiation and survival [24] . TWIST function in vertebrates governs early mesodermal patterning and osteogenesis [25] . Individuals with germ-line haploinsufficiency of the TWIST gene suffer from the hereditary disorder Saethre-Chotzen syndrome (acrocephakosyndactyly type III) characterized by premature craniosynostosis and limb, head, and face anomalies [26] . In cancer development, TWIST functions as a prometastatic oncogene. Expression of TWIST protein counteracts the proapoptotic effects of N-MYC by repression of p19ARF and thereby hampers TP53 function [27] .
At the DNA level, cancer development is characterized by genetic and epigenetic events. Methylation of CpG islands in promoter regions of tumor suppressor genes is a common epigenetic event [28] . Methylation abrogates proper TATA-binding protein binding to the promoter, leading to reduced expression of genes that play important roles in the cell cycle, cell adherence, cell signaling, DNA repair, and apoptosis [29] . Human breast carcinomas exhibit TWIST promoter hypermethylation at high frequency, ranging from 16% to 77% [2] [24] [30] . Moreover, methylation of the TWISTpromoter is a good predictor of human breast cancer presence [24] . These findings postulate methylation of the TWISTpromoter as an interesting breast cancer biomarker, but its functional significance remains unknown.
TWIST is a transcription factor that belongs to the basic-helix-loop-helix family and plays important role in cell differentiation and survival [6] . Hundreds of hypermethylated genes have been described in breast cancer. Scanlan et al, found 38% (37 out of 99) of Twist hypermethylation in breast cancer patients using quantitative multiplex methylation specific PCR (QM-MSP) [31] . In an another study conducted with Twist hypermethylation and type of tumor, they found Twist gene promoter was hypermethylated at a much lower frequency of 16% (3 of 19) in ILC compared to 56% (15 of 27) in IDC (p = 0.01) [32] . Gort et al. showed that promoter methylation of TWIST is significantly more prevalent in malignant compared to healthy breast tissue (34%) [9] . Shinozaki et al.
showed promoter region CpG hypermethylation was identified in 151 primary breast tumors, TWIST promoter hypermethylation occurs (48%) [33] . Sunami et al. showed TWIST metyhlation (37.5%) [34] . Li et al. showed TWIST hypermethylation (59%) [35] . We found decreased promoter methylation level (25%). We though that this can be caused by the tumor heterogeneity. intensity. This is an indication of DNA denaturation has been a very good track.
For this reason, the method is very high specificity and sensitivity. Very low rates of methylation differences can be detected.
Conclusions
In this study, we have demonstrated a significant association between methylated genes and known histopathological features in breast cancer patients in Turkey.
We have shown that DNA methylation can be assessed even small quantities of FFPE DNA. Also MS-HRM is a powerful technique in molecular biology for the detection of epigenetic changes and can be used for semi-quantitative estimation of methylation. MS-HRM also is practically advantageous for use in diagnostics, due to its capacity to be adapted to high throughput screening testing.
Determining the epigenetic changes observed in cancer cells and increasing data related to the issue is gradually becoming important in terms of prevention of cancer, determination of prognosis and development of therapeutic approaches.
This situation highlights the importance of methylation as a tumor marker.
Further examination of genes displaying high methylation levels in larger cohorts could provide for the early detection and/or disease monitoring and possibly for influencing therapeutic decisions.
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